

VIENNA Highlights

Spring & Summer 2019

Focus of dedicated biotech companies in Vienna

page 4-5

Vienna Stock Exchange welcomes Marinomed Biotech

page 8

Discover Austria's top life science location

Austria successfully brought the renowned biotech partnering conference “BIO-Europe Spring” to Vienna – and for good reason: The sector is growing and regularly offers impressive new business ideas, VC rounds, licensing deals, and M&As. Austria is home to more than 917 companies and 55 research institutions in the life science sector, over half of which are headquartered in Vienna.



© WienTourismus / Christian Stemper

Vienna is safe, Vienna is stable. And on top of this, Vienna is also the most livable city in the world. Join our vibrant biotech and medical device community and become one of our skyrocketing success stories! Vienna, the city of life and sciences is ready to accompany you on your way to

success. Benefit from an extremely tight network of funding opportunities, start-up offices, flexible lab space as well as everything else needed to start up life sciences companies and enable them to grow.

| www.LISAvienna.at



Dear readers!

We are pleased to introduce this special edition of our biannual Highlights publication. We hope

you enjoy reading this extended version on the occasion of BIO-Europe Spring, March 25-27 in Vienna!

To make it easier for you to identify potential partners, we have included a list of dedicated biotech companies in Vienna in this newsletter (pp. 4-5). For more information on our innovative enterprises and outstanding research institutions, please have a look at the Vienna Life Science Report 2018/19 and the Austrian Life Sciences Directory online. In addition, we invite you to contact the LISAvienna team with your requests at all the international trade fairs, partnering meetings and regional events we attend. We are happy to introduce you to our network and update you on the 360-degree support for life sciences start-ups in Vienna. Are you an entrepreneur-to-be or a newcomer? If so, consider participating in the international business plan competition aws BoB – Best of Biotech! There are separate tracks for early-stage projects and start-ups, and winners will receive €5,000, and €7,500 respectively. For both tracks, there are three categories of prizes: biotech/pharma, digital health and medtech. LISAvienna is sponsoring the medtech awards.

Did you know that Vienna is Central Europe's most important life science hot spot and is highly appreciated by global players as well? Indeed, most of the top 20 biotech, pharma and medtech companies based on worldwide sales have created a presence in the city. The Vienna region and other sites throughout Austria are perfectly suited for R&D and for manufacturing drugs and medical devices for users around the globe. On page 11, we present some of the international groups that are playing a key role in Austria in this regard.

Have a great trade fair season and don't hesitate to contact us.

Peter Halwachs and Johannes Sarx
 LISAvienna Executive Board

Meet us at trade shows & exhibitions

BIO-Europe Spring 2019
 Vienna, March 25-27, 2019

DMEA 2019
 Berlin, April 9-11, 2019

BioTrinity 2019
 London, April 30 – May 1, 2019

MedtecLIVE & MedTech-Summit
 Nürnberg, May 21-23, 2019

dHealth 2019
 Vienna, May 28-29, 2019

BIO International Convention
 Philadelphia, June 3-6, 2019

Intelligent Health
 Basel, September 11-12, 2019

EFIB 2019
 Brussels, Sept 30 – Oct 2, 2019

in cooperation with:



We reserve the right to make changes.

Need a lab for your start-up in Vienna?
Please contact the LISAvienna team!

LISAvienna – Connecting Life Sciences

We offer core services at no charge

Joint life science platform for the advancement of life sciences in Vienna



Personalized support for innovative biotech, pharmaceutical and medical device companies

- in Vienna,
- that develop and market
- new products, services and processes

Connecting companies with development partners and key customers.



© LISAvienna / Beranek

Your partners at LISAvienna (ltr): Andrea Jan Coleselli (Administration, Controlling and Events), Johannes Sarx (Managing Director), Brigitte Tempelmaier (Project Manager Marketing & PR), Peter Halwachs (Managing Director), Martin Mayer (Technology Expert Medtech), Jürgen Fuchs (Technology Expert Biotech & Pharma)

Contact us and benefit from our services



Information & Consulting:

Tips and contacts relating to sponsorship, private financing options, lab space in Vienna, development partners, leading customers and internationalization



Networking & Matching:

Contacts for an improved exchange of experiences and knowledge transfer as well as contact with development partners, leading customers and investors worldwide



Expertise:

Analyses, background information, reports and studies relating to life sciences in Vienna



Marketing:

Electronic and printed news items from the field of life sciences in Vienna

Newsletter & Tweets

Stay updated on the hottest news from the life science city Vienna!


Subscribe to our newsletter at LISAvienna.at

Follow us on Twitter [@lifesciencevienna](https://twitter.com/lifesciencevienna)

Biotech, Pharma & Medtech growing in Vienna

Vienna is Austria's prime location for life sciences. More than half of Austria's 917 companies and 55 research institutions are located here and together employ half of the sector's workforce.

Vienna has an excellent scientific tradition in the field of medical research. Semmelweis, Billroth and Landsteiner are part of its history. The outstanding reputation of the Vienna Medical Schools in the past is carried on today – in academia and in business. Vienna's life science community has experienced significant growth over many years. In 2017, a total of 554 companies, research institutions and further core organizations were active in the life science sector in Vienna, having a combined workforce of 37,595 people.



Global players and startups appreciate Vienna

The sector's significance is shown by its revenues of around €12.2 billion in 2017, over 34,700 students, more than 4,600 internationally recognized publications, as well as 84 ERC grants. Compared to 2014, the numbers show a 5% increase in employment and a 23% increase in revenue. This development is due to high international demand for the products and services offered by pharma, biotech, and medtech companies, strong investments in manufacturing plants to increase production capacities, and a dynamic startup culture.

Biotechnology's growth course

Dedicated biotechnology companies – i.e. those that are mainly focused on biotech – are enjoying continued growth in Vienna. From 50 companies in 2012, their numbers increased to over 67 in 2014 and 78 in 2017. In Vienna, medical biotechnology again leads by a clear margin. The top three themes within this powerhouse sector remain infectious diseases, cancer, and respiratory diseases. By the end of 2017, Vienna's dedicated biotechnology companies reported a total of 77 new therapeutic substances in the pipelines. In addition, Vienna's biotech community focuses on diagnostics, research reagents, bioeconomy and sector-specific services including bioinformatics.

Leading city for new eHealth solutions

The number of dedicated medical device companies has risen by 50% since 2012, with 46 companies now calling Vienna home. The current numbers confirm long-standing strengths in electromechanical medical devices, special products for people with physical disabilities, as well as disposable products. However, the dynamic development of software solutions for the medical sector, including eHealth tools, is outstanding: from seven companies in 2012 (and 10 in 2014) the number has grown to 20 companies, thus nearly tripling within five years. This development makes Vienna a leading city in digital health.



Pick up a copy of these publications at the trade fairs and partnering meetings we attend and search for partners at

www.lifesciencesdirectory.at

FREE download at www.LISAVienna.at

Focus of dedicated biotech companies in Vienna

		Health related topics														Industrial applications	Agriculture & environment	Bioinformatics	Other			
		Blood & the immune system	Circulatory system	Digestive system	Endocrine & metabolic diseases	Eye and the ear	Genitourinary system	Infectious diseases	Musculoskeletal system	Neoplasms	Nervous system	Respiratory system	Skin & subcutaneous tissue	Other medical topics, tools, reagents, veterinary issues								
1	ab&cd innovations GmbH																		●			
2	Albevia biotech GmbH	●																				
3	Accanis Biotech F&E GmbH & Co KG																					●
4	Acticell GmbH																					●
5	Aelian Biotechnology GmbH																					●
6	AFFIRIS AG		●		●						●											●
7	Akribes Biomedical GmbH													●								●
8	AlgOss Biotechnologies GmbH																					●
9	Allcyte GmbH	●																				●
10	APEIRON Biologics AG	●								●		●										●
11	APEPTICO Forschung und Entwicklung GmbH				●							●										●
12	Aposcience AG													●								●
13	Ares Genetics GmbH							●														●
14	Arsanis Biosciences GmbH							●				●										●
15	Attoquant Diagnostics GmbH		●																			●
16	Austrianni GmbH							●														●
17	Bio-Products & Bio-Engineering Aktiengesellschaft	●							●			●	●									●
18	Biomay AG											●	●									●
19	Biomedical International R+D GmbH									●		●										●
20	Biomedizinische Forschungsgesellschaft m.b.H.	●								●												●
21	Bioplant R & D																					●
22	BIRD-C GmbH & Co. KG			●				●					●									●
23	Blue Sky Vaccines KG									●												●
24	BS-Immun GmbH																					●
25	emergentec biodevelopment GmbH																					●
26	enGenes Biotech GmbH																				●	●
27	Epsilon 3 GmbH																					●
28	EUCODIS Bioscience GmbH																				●	●
29	Eurofins Genomics AT GmbH																					●
30	EveliQure Biotechnologies GmbH			●				●														●
31	Evercyte GmbH																					●
32	Evologic Technologies GmbH																				●	●
33	F-star GmbH										●											●
34	F2G Biotech GmbH										●											●
35	F4 Pharma GmbH in Gründung	●	●								●											●
36	Haplogen GmbH				●			●				●										●
37	HG Pharma GmbH	●	●	●	●			●			●	●		●								●
38	Hookipa Pharma Inc.									●		●										●
39	ingenetix GmbH																					●
40	Labdia Labordiagnostik GmbH							●		●												●

● Area of activity

		Health related topics												Industrial applications	Agriculture & environment	Bioinformatics	Other		
		Blood & the immune system	Circulatory system	Digestive system	Endocrine & metabolic diseases	Eye and the ear	Genitourinary system	Infectious diseases	Musculoskeletal system	Neoplasms	Nervous system	Respiratory system	Skin & subcutaneous tissue					Other medical topics, tools, reagents, veterinary issues	
41	Lexogen GmbH																		●
42	Marinomed Biotech AG				●		●				●								
43	Mark53 GmbH								●				●						
44	Microsynth Austria GmbH																		●
45	Miti Biosystems GmbH												●						●
46	MVT Biotechnology GmbH						●												
47	Mycoplasma Biosafety Services GmbH												●						●
48	Myelopro Diagnostic and Research GmbH								●										
49	NABRIVA Therapeutics AG			●	●	●	●				●	●							
50	NBS-C BioScience & Consulting GmbH	●									●		●						
51	NuVonis Technologies GmbH												●						
52	OncoLab Diagnostics GmbH								●				●						
53	Origimm Biotechnology GmbH												●						
54	Panoptes Pharma Ges.m.b.H.				●		●												
55	PhagoMed Biopharma GmbH					●	●	●											
56	Phenaris Softwareentwicklungs- und consulting GmbH												●						●
57	Planta Naturstoffe Vertriebsges.m.b.H.								●	●									
58	Platomics GmbH												●						●
59	Ribbon Biolabs GmbH																		●
60	S-TARget therapeutics GmbH										●								
61	SAICO Biosystems KG												●						
62	Savira pharmaceuticals GmbH							●											
63	Syconium Lactic Acid GmbH															●			
64	TAmiRNA GmbH		●		●				●				●						
65	Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH	●	●										●						
66	The Antibody Lab GmbH	●	●	●	●					●			●						
67	Themis Bioscience GmbH									●									
68	Thoeris GmbH				●														
69	Tube Pharmaceuticals GmbH									●									
70	Vacthera BioTech GmbH									●	●								
71	Valneva SE										●								
72	VelaLabs GmbH												●						
73	VIDIPHARM GmbH												●						
74	ViennaLab Diagnostics GmbH	●	●	●	●		●		●			●	●						
75	Viravaxx AG																		
76	Virusure GmbH												●						
77	Vita 34 Gesellschaft für Zelltransplantate m.b.H.												●						
78	Vivaldi Biosciences AG																		
79	YASARA Biosciences GmbH																		●
80	Zytoprotec GmbH					●													

This list is not exhaustive.

aws Business Plan Competition

BoB – Best of Biotech

Entrepreneurs-to-be and start-ups from around the globe are invited to participate in this international competition. There are separate tracks for early stage projects and start-ups, and winners will receive € 5,000, and € 7,500 respectively. For both tracks, there are three categories of prizes:

- Biotech/pharma
- Digital health
- Medtech

LISAVienna is happy to sponsor the medtech awards.

Check out further details at www.bestofbiotech.at and submit your pitch deck or business plan by June 27, 2019!

WORK, SHARE AND GROW

Start-up Labs Vienna Biocenter

Opening in 2019

- 1,100 m² of start-up atmosphere
- Basic equipment available
- Move in and get to work
- No minimum rental period
- Lab space starting at € 300/month
- Office space starting at € 250/month

www.viennabusinessagency.at

Valneva hits the headlines

- New \$59 million IXIARO® supply contract with US government
- Initiation of Phase 2 clinical development for Lyme Disease vaccine candidate
- Positive Phase 1 interim results and FDA fast track designation for chikungunya vaccine candidate#

www.valneva.com

SCARLETRED: Austria's most successful eHealth crowd campaign concludes with a total funding of € 597,950

scarletredvision.com

Co-Creation Lab Vienna

Are you looking for an innovative solution to a business challenge or do you need new ideas from other companies or research institutions? Established businesses and organizations with a clear link to Vienna are invited to participate in the Vienna Business Agency's Co-Creation Lab Vienna program. Specify your needs and develop innovative solutions together with partners.

www.viennabusinessagency.at



Harald Schnidar, CEO
SCARLETRED Holding GmbH

“ SCARLETRED is located at the Vienna BioCenter, a highly dynamic life science hot spot at the heart of Europe. This allows us to access a unique R&D infrastructure and facilitates recruiting of talents for growing our business. Regional and national funding schemes support us along this path. Our international partners appreciate the Vienna BioCenter's proximity to the Vienna International Airport. This is ideal for promoting AI powered skin imaging and analysis.”

Vienna Science and Technology Fund to open “Multimodal Imaging” project call

Researchers at universities and non-university research institutions in Vienna, including those moving to Vienna, who wish to conduct a cutting-edge research project (from 2 to 4 years; €200,000-700,000) in the field of multimodal bioimaging are invited to apply. €4 million have been earmarked for this call.

www.wvtf.at

Themis Bioscience: Follow the journey to bring immune-modulation products to patients

- Compelling Phase 2 results for lead vaccine candidate against Chikungunya fever
- Exclusive licensing agreement with Max-Planck-Innovation to develop and commercialize oncolytic virotherapies
- EMA PRIME designation for Chikungunya vaccine

www.themisbio.com

Two companies from Vienna selected for the Philips Healthworks AI in Radiology Accelerator:

- contextflow GmbH: 3D image-based information search solution for radiology
- IB Lab GmbH: software to predict and diagnose bone diseases

Only 19 start-ups out of over 750 international applications have been invited to participate in this 12-week program.

123Sonography acquires the SonoWorld website from Inteleos

With the acquisition of SonoWorld, 123sonography is cementing its position as the #1 online provider of ultrasound education. More than 400,000 registered ultrasound professionals around the world appreciate the company's top-quality, educational online content.

www.123sonography.com

HOOKIPA Pharma in the news

- First research milestone in HIV collaboration and license agreement with Gilead achieved
- First patient in a Phase 2 clinical trial of prophylactic vaccine candidate HB-101 against Cytomegalovirus dosed
- Research collaboration and license agreement entered with DarwinHealth

www.hookipapharma.com

Expatriate in Vienna

The Expat Center at the Vienna Business Agency is the central point of contact for highly qualified professionals and executives. A team of experts provides free advice and assistance on all aspects of their professional and private start in Vienna. Join our Expat Club to grow your network with the international community, get to know the Viennese and feel at home in the city.

www.viennabusinessagency.at

Vienna Business Agency invests in the future of healthcare

Using a rigorous evaluation procedure, the Vienna Business Agency is funding 12 business R&D projects through its Healthcare Call 2018. € 3.47 million have been granted to projects such as:

- **Ares Genetics GmbH:** AI & Assays for Detecting Antibiotic Resistance
- **Blue Sky Vaccines GmbH:** Novel Immunotherapy against HPV-induced cancer
- **contextflow GmbH:** AI-powered 3D image search engine for radiologists
- **FemPulse GmbH:** Bioelectronic medicine - Future of women's health
- **IB Lab GmbH:** Software-based detection of distal radius fractures
- **Ing. Sumetzberger GmbH:** Autonomous Robot Transport System - Smart Cabinet
- **piur imaging GmbH:** Tomographic ultrasound-based angioplasties
- **usePAT GmbH:** Ultrasound technology for bio-based process control

www.viennabusinessagency.at

vienna
business
agency

A service offered by
the City of Vienna

Sanochemia Pharmazeutika AG announces grant of patent for Vidon® Photodynamic Bladder Cancer Therapy in the USA

Vidon® (PVP-Hypericin) is one of Sanochemia's promising pipeline products and is being developed as a game-changing technology in the management of bladder cancer. The patent covers the bladder cancer therapy method using Sanochemia's developed PVP-Hypericin formulation.

Lexogen supports thousands of RNA researchers worldwide by partnering with the RNA Society in their 2018/19 RNA Salon initiative

www.lexogen.com

I ♥ Vienna

Vienna Stock Exchange welcomes Marinomed Biotech

With the successful IPO, the shares of Marinomed Biotech AG started trading in the top segment of the Vienna Stock Exchange in February. The IPO of Marinomed Biotech AG is the first in Europe this year. Market supply and demand determined the first stock market price of 75.5 EUR.

Marinomed's business focus is on the development of innovative products for respiratory and eye diseases based on patented technology platforms. The market capitalisation of the globally-active Vienna-based biopharmaceutical company computed on the opening price was EUR 95.13 million (excl. greenshoe). The start of trading was traditionally celebrated with the bell-ringing ceremony.

In his keynote speech, Marinomed CEO Andreas Grassauer said: "Our presence on the Vienna Stock Exchange and our dialogue with investors puts us in an even better position to achieve our growth targets. The IPO ensures the highest degree of international attention for our company". Christoph Boschan, CEO of the Vienna Stock Exchange and its holding company, said "Marinomed wants to conquer the world market. And we are a very international stock exchange and use the world's leading trading technology. So it is a wonderful fit."

www.marinomed.com

Andreas Grassauer
(CEO Marinomed) and
Christoph Boschan
(CEO Vienna Stock Exchange)



VIENNA

Other big equity investments

Arsanis

www.arsanis.com

Monoclonal antibody immunotherapies for serious infectious diseases

Q4/17

€ 51 million IPO in NY

Q2/17

€ 41 million

series D financing

Hookipa Pharma

www.hookipapharma.com

Active immunization therapies for infectious diseases and cancer

Q4/17

€ 50 million

series C financing

Nabriva Therapeutics

www.nabriva.com

Innovative anti-infective agents to treat serious infections

Q3/18

\$ 50 million public offering

Q4/17

€ 67 million capital

increase

Valneva

www.valneva.com

Innovative life-saving vaccines for infectious diseases

Q3/18

€ 50 million private

placement

Why Vienna?

© Themis Bioscience / Stefan Krittler



Erich Tauber

CEO of Themis Bioscience GmbH

“Vienna has become a biotech hotspot over the last years combining a great deal of scientific and entrepreneurial expertise, especially in the fields of immunology and infectious disease research. The excellent academic infrastructure in these areas is represented, for example, by the “Immunology” and “Oncology” research cluster of the MedUni Vienna, and a high density of companies have emerged from the excellent local institutions, contributing to the innovative climate. This overall package makes Vienna a very attractive location for Themis Bioscience.”

“Vienna offers the possibility of cooperation with partners in the medical field, such as leading physicians of the MedUni Vienna, which is essential for our research work. This, in combination with the cosmopolitan, multicultural atmosphere in a city with a proven high quality of life, makes it possible to attract highly qualified specialists to the location. The expertise secured in this way feeds directly into the development of our technologies and innovative products in order to enable users to improve their quality of life.”



© Ottobock

Andreas Goppelt

Ottobock CTO and Managing
Director at the Vienna subsidiary
Ottobock Healthcare Products GmbH

© Octapharma



Barbara Rangetiner

General Manager at Octapharma
Pharmazeutika Produktionsgesellschaft m.b.H.

“Every day we strive to provide safe and efficacious treatments for our patients around the world. By extension of our basic fractionation we'll be able to double our plasma throughput within the next years. Vienna with its central location, the excellent educational opportunities and its good infrastructure offers best conditions for generating additional jobs to meet the growing demand for our life-saving products in the future.”



© Boehringer Ingelheim
Marion Garniel

Philipp von Lattorff

Managing Director
at Boehringer Ingelheim
RCV GmbH & Co KG

“Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.”

© Agnes Stadlmann



Eva Prieschl-Grassauer

CSO at Marinomed Biotech AG

“Vienna is the life science hotspot in Europe. The city bears excellent infrastructure in general and a set of universities with outstanding life science research develops the talents for the future. Marinomed's listing on the Vienna stock exchange now enables us to focus on projects of the Marinosolv technology platform, in particular Budesolv and Tacsosolv, both targeting the allergy market.”



© APEIRON Biologics
Bernhard Peßall

Peter Llewellyn-Davies

CEO of APEIRON Biologics AG

“The quality of our home base in Vienna combined with the broad support for research and development in the biotech industry are excellent and inspiring. The close cooperation of industry and academia, plus the generous grants from government bodies, have enabled and provided substantial support for our efforts to develop new treatment options to devastating diseases. Our proprietary master checkpoint blockade mechanism was discovered in Vienna – thanks to the availability of qualified staff, partners and experienced service providers.”

START-UP ECOSYSTEM IN VIENNA


360° Support for the Life Sciences

Vienna:

- Highest quality of life worldwide
- Largest talent pool in the German speaking region
- Outstanding basic and clinical research
- Prime conference destination

Austria:

- Stable political and economic framework
- 14% research tax credit
- Maximum corporate tax rate: 25%
- Tailor-made funding opportunities



We accompany you on your way to success. Enter the ecosystem now!



LISAvienna.at



investinaustria.at



aws.at



FFG.at



FWF.ac.at



INiTS.at



lifescienceaustria.at



viennabusinessagency.at



wko.at/wien/aw



wwtf.at

Manufacturing drugs and medical devices in Austria

The Vienna region and other sites throughout Austria are highly appreciated by internationally oriented global businesses in the life sciences. Almost all of the top 20 companies carry out marketing and sales, manufacturing or R&D in Austria. Innovative solutions made in Austria serve patients around the globe. Several big players are currently expanding their manufacturing facilities to increase the production capacities for drugs and medical devices to serve the international market.

Boehringer Ingelheim

Boehringer Ingelheim develops and manufactures biopharmaceuticals in Vienna both from its own research and on contract for other clients. In early 2017, the company started construction on a new biopharmaceutical production facility and associated infrastructure, which will become operational in 2021. It calls for an investment of almost € 700 million. Boehringer Ingelheim employs some 1,690 people in Vienna.

www.boehringer-ingelheim.at

MED-EL

MED-EL Medical Electronics, a leader in implantable hearing solutions, is driven by a mission to overcome hearing loss as a barrier to communication. The Austrian-based, privately owned business was co-founded by industry pioneers Ingeborg and Erwin Hochmair, whose ground-breaking research led to the development of the world's first micro-electronic multi-channel cochlear implant (CI). To date, MED-EL has grown to more than 2,000 employees and 33 subsidiaries worldwide.

www.medel.com

Novartis

The Austrian Novartis Group is one of the leading pharmaceutical companies in the country, employing more than 4.000 employees mainly in Tyrol, Upper Austria and Vienna. Novartis offers innovative as well as generic medicines to patients and is closely working with Austrian medical centers of excellence, sponsoring 100 clinical trials involving around 3,000 patients. Novartis is currently investing € 200 million in manufacturing facilities in Tyrol.

www.novartis.at

Octapharma

Octapharma, a family-owned company and one of the largest human protein manufacturers in the world is developing and producing human proteins from human plasma and human cell-lines serving patients in 113 countries. In Vienna, around 1.200 employees contribute to developing and manufacturing high-quality life-saving products for the therapeutic areas of hematology, immunotherapy and critical care. Octapharma believes in investing to make a difference in people's lives.

www.octapharma.at

Ottobock

All around the world, Ottobock is known for high-quality, technologically outstanding products and services in the field of medical technology. Products developed and produced in Vienna, improve the quality of life of users all over the world. Ottobock currently has 650 employees in Vienna, approximately one third working in research and development.

www.ottobock.at



Pfizer

Pfizer researches and develops pharmaceuticals and health products that make an impact across all stages of life and serves customers in more than 80 countries. In Lower Austria, Pfizer is manufacturing two vaccines for global demand. The Vienna subsidiary is supplying medicines to the Austrian market and is a reliable partner for patients, doctors, pharmacists and the healthcare system. Pfizer employs 520 people in Austria.

www.pfizer.at

Sempermed

Sempermed is the Medical Sector of Semperit Group and one of the world's leading producers of medical gloves. Sempermed's manufacturing plants and the entire manufacturing process are subject to very stringent quality tests and are regularly checked by TÜV and local authorities. Semperit Group employs around 900 people in Austria and operates a major manufacturing plant in Wimpassing, Lower Austria.

www.sempermed.com

Takeda

Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing better health to people worldwide. In Austria, Takeda is manufacturing several life-saving drugs and operates a pharma marketing unit. Roughly 4,500 employees in Austria contribute to delivering highly innovative medicines and transformative care to people around the globe.

www.takeda.com/de-at

Welcome to Vienna BIO-EUROPE SPRING®

MARCH 25-27, 2019 // VIENNA, AUSTRIA

Austria is proud to host BIO-Europe Spring 2019. All European key decision makers in biotech will gather to discuss tomorrow's investments, M&As and partnering agreements. Conference participants will find themselves in the center of Austria's prospering life science community. Informal networking receptions and site visits will complete the prime daytime program.

Sunday, March 24: Vienna City Hall

Vienna City Hall | Lichtenfelsgasse 2 | Feststiege 1 | 1010 Vienna

Friedrich von Schmidt designed and built Vienna's City Hall, the most important secular building in the neo-Gothic style in the city, between 1872 and 1883. It is here where the Mayor, the city senate, and the municipal council convene.

Sunday, March 24, 2019, 7-9 p.m.

*Sponsored by LISAvienna
Venue provided by the City of Vienna*



© WienTourismus / Christian Stemper

Monday, March 25: HOFBURG Vienna

HOFBURG Vienna | Heldenplatz 1 | 1010 Vienna

Dating back to the 13th century, Vienna's Imperial Palace is one of the largest palace complexes in the world and was the former residence of the Habsburgs. This prestigious building is the official seat of the Austrian Federal President.

Monday, March 25, 2019, 7-10 p.m.

*Venue provided by the Federal Ministry for
Digital and Economic Affairs*



© Hofburg Vienna / Manfred Seidl

Tuesday, March 26: Exhibit Hall Hospitality Reception

Life Science Austria booth #50

Meet us for beer and traditional sausages at the LISA booth and learn about collaboration and investment opportunities in Austria. Are you planning to set up a company here or to expand your business to Austria? We are ready to accompany you on your way to success!

Tuesday, 26 March 2019, 5:45 - 6:45 p.m.

Supported by ABA - Invest in Austria



© LISAvienna

Tuesday, March 26: Gösserhalle

Gösserhalle | Laxenburgerstraße 2B | 1100 Vienna

Over 120 years old, Gösserhalle served as a warehouse for beer, which was delivered in wooden barrels to taverns around Vienna by horse-drawn carriages. Today, visitors love the charming venue's shabby-chic flair.

Tuesday, March 26, 2019, 7-11 p.m.

Co-Sponsor: Boehringer Ingelheim



© Gösserhalle / Georg Krewenka

Site visits: Thursday, March 28

Join top-class site visits and learn more about Vienna's life science community.

The number of participants is limited. Please contact the LISAvienna team at booth #50 for details.

It is our pleasure to have the winners of the Start Alliance program "Discover Vienna: Life Sciences" operated in collaboration with the Vienna Business Agency, join the tours!

LISAvienna
Life Science Austria Vienna
Walcherstrasse 11A
1020 Vienna, Austria

PHONE +43 (0) 1 50175 358
FAX +43 (0) 1 50175 900
E-MAIL office@LISAvienna.at
WEB www.LISAvienna.at

LISAvienna is a joint life science platform operated by austria wirtschaftsservice and the Vienna Business Agency. On behalf of the Austrian Federal Ministry for Digital and Economic Affairs and the City of Vienna, LISAvienna contributes to the advancement of life sciences in Vienna.